187 filings
Page 5 of 10
8-K
ii4 xofwhdptsb1gxcg
15 Jan 19
Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
5:15pm
8-K
818q4k3 ue0p5l4i
4 Jan 19
Marker Therapeutics Provides Updates of its Lead Clinical Programs
12:34pm
8-K
ohr8 slpzrnfrzll
4 Dec 18
Other Events
12:00am
8-K
lbsv7 g9zt
3 Dec 18
Departure of Directors or Certain Officers
4:12pm
8-K
mngww0g nmfmq
27 Nov 18
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
4:58pm
8-K
wgmv0o8o9pynrg9s2l8
27 Nov 18
Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
9:15am
8-K
redj8 sr599gj4913co
30 Oct 18
Other Events
4:18pm
8-K/A
csdrnx3t779nrz
29 Oct 18
Financial Statements and Exhibits
12:00am
8-K
mr2ziq7sinkm1h5
23 Oct 18
Marker Therapeutics, Inc. Announces New Executive Appointments
5:08pm
8-K
dh6r p9cub
17 Oct 18
Tapimmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing
4:00pm
8-K
qyw5tpwnt2 n82ez8xm
8 Aug 18
Other Events
4:40pm
8-K
t9acjre0cdr i6rlo
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
8-K
a812injk8kqd47juayq
18 May 18
Entry into a Material Definitive Agreement
5:16pm
8-K
ajjll0y
15 May 18
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
6:07am
8-K
kt975kg9dhw
25 Sep 17
TapImmune Appoints Peter Hoang as President and Chief Executive Officer
12:00am
8-K
xzkncg8 3vz
5 Sep 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
sme421h
11 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
xcirg7s8vbr3zg3ntj0
26 Jun 17
Unregistered Sales of Equity Securities
12:00am
8-K
vipybh
22 Jun 17
TapImmune Inc. Enters into Definitive Agreements to Raise
12:00am
8-K
h6d n0l757i
28 Apr 17
TapImmune Announces Change in Management and Board of Directors
12:00am